抗菌肽Lfcin15-Me8分子设计及对老年呼吸道致病菌铜绿假单胞菌的抑菌性能分析

Molecular Design of Antimicrobial Peptide Lfcin15-Me8 and Its Inhibition Performance Analysis on Respiratory Tract Pathogenic Pseudomonas aeruginosa in Senile

探讨人工设计合成的Lfcin15-Me8分子对老年病患者中铜绿假单胞菌抑菌活性研究。从老年病患痰液中分离鉴定铜绿假单胞菌(Pseudomonas aeruginosa)感染情况,截取牛乳铁蛋白素(Lfcin B)1-15和蜂毒素(Melittin)1-8核心氨基酸序列,固相合成新型抗菌肽分子,采用微量肉汤稀释法,测定新型抗菌肽分子对临床分离菌株的抑菌活性。结果显示,铜绿假单胞菌占院内感染的32.2%,位列致病菌第二位。合成的新型抗菌肽分子Lfcin15-Me8,为阳离子型抗菌肽,并富含α-螺旋。对临床铜绿假单胞菌抑菌MIC值均达到128μg/m L以下,其中最低达到32μg/m L,具有良好抗菌活性。铜绿假单胞菌在老年呼吸道感染中占较大比重,需注意防控,人工合成的Lfcin15-Me8分子可抑制临床铜绿假单胞菌的生长繁殖。

Antibacterial activity of artificially designed,synthesized antimicrobial peptide（ AMP） Lfcin15-Me8 against Pseudomonas aeruginosa isolated from geriatric patients was investigated. Infection status of P. aeruginosa isolatedand identified from sputum of geriatric patients was carried out. A novel antimicrobial peptide（ AMP）Lfcin15-Me8 was designed base on cut-out core amino acid sequence of bovine lactoferricin（ Lfcin 1-15） and mellitin（ mellitin 1-8）,and obtained by solid phase synthesis. The inhibition activity of the novel AMP molecule on clinical isolated strains was determined adopting trace broth dilution method. The results showed that the specific gravity of infection within the hospital of P. aeruginosa account for 32. 2%,located at the second place among the pathogens. The synthetic novel AMP molecule Lfcin15-Me8 was classified as cationic AMP and rich inα-helix. The minimum inhibition concentration（ MIC） against clinical P. aeruginosa was all below 128 μg /m L,among them the lowest was at 32 μg / m L,possessing fine antibiotic activity. P. aeruginosa occupied fairly high specific gravity among respiratory tract infection in geriatric patients,it needs prevention and control,the artificialsynthetic Lfcin15-Me8 could inhibit the growth and propagation of clinical P. aeruginosa.